Labcorp Holdings Inc. (LH) Stock Price & Analysis
Labcorp Holdings Inc. (LH) rose 1.98% to USD 296.77 as of July 25, 2026 at 01:45 UTC, according to Nexqual real-time market data.
LH last closed at USD 291.02; the session ranged USD 290.22–298.58 on volume of 776,997 shares. Market capitalization is —, with a 52-week range of USD 244.52–298.58 (NYQ). Source: Nexqual, July 25, 2026 at 01:45 UTC.
Key Statistics (as of July 25, 2026 at 01:45 UTC)
| Price | USD 296.77 |
|---|---|
| Change | ▲ 1.98% (up) |
| Previous Close | USD 291.02 |
| Open | USD 292.12 |
| Day Range | USD 290.22 – 298.58 |
| 52-Week Range | USD 244.52 – 298.58 |
| Volume | 776,997 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (LH)
Nexqual's technical model rates LH "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:45 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.85 (neutral) |
| vs SMA50 | Above (USD 268.51) |
| MACD | 5.42 (positive) |
Analyst Ratings (LH)
Wall Street analysts rate LH "Buy" based on 17 analysts, with a mean price target of USD 312.35 (range USD 270–340), per Nexqual as of July 25, 2026 at 01:45 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 312.35 |
| High Target | USD 340 |
| Low Target | USD 270 |
| Buy / Hold / Sell | 14 / 5 / 0 |
Earnings (LH)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 4.77 |
| Revenue Estimate | $3.71B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.25 vs est 4.12 ▲ beat |
| 2025-12-31 | USD 4.07 vs est 3.94 ▲ beat |
| 2025-09-30 | USD 4.18 vs est 4.14 ▲ beat |
| 2025-06-30 | USD 4.35 vs est 4.16 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financials & Fundamentals (LH)
| Total Revenue | $14.14B |
|---|---|
| Revenue Growth (YoY) | +5.80% |
| Gross Margin | +28.83% |
| Operating Margin | +10.95% |
| Profit Margin | +6.66% |
| ROE | +11.05% |
| Debt / Equity | 83.41 |
| Current Ratio | 1.73 |
| Total Cash | $981.10M |
| Total Debt | $7.29B |
| Free Cash Flow | $1.14B |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financial Health Score (LH)
Nexqual rates Labcorp Holdings Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:45 UTC.
| Growth | Solid — Revenue +6% YoY (latest Q) |
|---|---|
| Profitability | Solid — Gross margin 29%, operating 11% |
| Balance Sheet | Mixed — $981M cash vs $7.29B debt |
| Cash Flow | Solid — FCF $1.14B, 8% margin |
| Efficiency | Mixed — ROE 11%, ROA 5.3% |
Ownership (LH)
| Insider Ownership | +0.35% |
|---|---|
| Institutional Ownership | +101.09% |
| Float | 81.60M |
| Short % of Float | +3.46% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Leadership (LH)
Labcorp Holdings Inc. is led by Adam H. Schechter (age 60), President, CEO & Chairman, per Nexqual as of July 25, 2026 at 01:45 UTC.
| President, CEO & Chairman | Adam H. Schechter (age 60) |
|---|---|
| CFO & Executive VP | Julia A. Wang (age 53) |
| EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | Brian J. Caveney J.D., M.D., M.P.H. (age 51) |
| Executive VP and President of Central Laboratory Services & International Labcorp | Megan D. Bailey M.P.H. (age 45) |
| Vice President of Investor Relations | Christin O'Donnell |
Major Backers & Investors (LH)
Notable institutional backers of Labcorp Holdings Inc. include Victory Capital Management Inc., Boston Partners, Allspring Global Investments Holdings, LLC, according to Nexqual as of July 25, 2026 at 01:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Victory Capital Management Inc. | 5.64% |
| Boston Partners | 2.89% |
| Allspring Global Investments Holdings, LLC | 2.72% |
| Select Equity Group LP | 2.65% |
| JPMorgan | 1.87% |
| ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund | 1.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.91% |
| BlackRock | 9.19% |
| State Street | 5.92% |
| Geode Capital | 2.67% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
From Labcorp Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Labcorp Holdings Inc. provides laboratory services.
- It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments.
- The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
- It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DGX | Quest Diagnostics Incorporated | USD 227.86 | ▲ 8.59% |
| WAT | Waters Corporation | USD 374.68 | ▲ 1.04% |
| UHS | Universal Health Services, Inc. | USD 155.75 | ▲ 4.29% |
| IQV | IQVIA Holdings, Inc. | USD 208.05 | ▲ 4.8% |
| MTD | Mettler-Toledo International, I | USD 1,327.18 | ▲ 3.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:45 UTC. This page is informational and not investment advice.